Piper Sandler analyst David Westenberg reiterated a Hold rating on Myriad Genetics (MYGN – Research Report) today and set a price target of $23.00. The company’s shares closed yesterday at $23.50.
According to TipRanks, Westenberg is a 3-star analyst with an average return of 2.1% and a 48.30% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Illumina, Myriad Genetics, and Exact Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Myriad Genetics with a $24.00 average price target, a 2.13% upside from current levels. In a report released yesterday, TD Cowen also maintained a Hold rating on the stock with a $26.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
MYGN market cap is currently $1.87B and has a P/E ratio of -6.82.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Myriad Genetics (MYGN) Company Description:
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual’s risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Read More on MYGN:
- Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
- Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
- MYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
